May 16, 2015

nanoRETE to Present at the 2015 Michigan Growth Capital Symposium

nanoRETE has been selected to present at the 2015 Michigan Growth Capital Symposium May 19-20, 2015. The company is among a roster of promising, high-growth companies from the Midwest and beyond seeking funding in the next 12 months. nanoRETE will present to attending investors, which include nearly 100 regional and top national venture capital firms.

The Michigan Growth Capital Symposium, known for attracting high-quality investors from around the country, is the oldest university-based venture capital fair and the premier Midwest networking event for leaders in venture capital investment. Now in its 34th year, the Symposium serves as a conduit for introducing early stage and emerging growth companies seeking funding to U.S. investors prospecting deals.

“The influx of innovation, venture capital and entrepreneurial activity continues to boom in the Midwest,” said David J. Brophy, Michigan Growth Capital Symposium founder and director and professor of finance at the University of Michigan Ross School of Business. “nanoRETE is an example of a high caliber organization homegrown in Michigan and a testament to why investors across the country are paying closer attention to the region.”

March 2, 2015

nanoRETE to launch preclinical verification trial

nanoRETE is launching a preclinical verification trial, in collaboration with the Kent County Health Department and Mercy Health Saint Mary’s. The trial will also include an analysis comparing the nanoRETE screening test against market comparable tests. The Grand Rapids, Michigan-based trial will enable the company to work directly with clinical teams and participate in sample receipt and handling. A total of 100 samples (50 infected and 50 uninfected) will be collected through the collaboration.

February 17, 2014

Dr. Stephen Treisenberg joins nanoRETE Scientific Advisory Board

Dr. Stephen Treisenberg, MD, Division Chief for Infectious Disease at Spectrum Health Medical Center has joined the nanoRETE Scientific Advisory Board. Dr. Treisenberg leads the tuberculosis clinic at Kent Community Hospital, and provided the opportunity for nanoRETE to conduct primary market research in-clinic. The need for new diagnostic tools was clearly demonstrated.

May 9, 2013

nanoRETE, Inc. Receives Air Force SBIR Contract for Development of Pathogen Biosensor

nanoRETE, Inc. announced today that it has been awarded a Phase II contract under the Air Force Small Business Innovation Research (SBIR) program for the continued development of a “field-appropriate biosensor for the detection on Mycobacterium tuberculosis infection,” a latently infectious form of TB. The award enables nanoRETE to build upon proprietary technology developed under the previously completed SBIR Phase I contract.

Development work will take place over a two year period, with an estimated funding level of $750,000. The company has also been awarded a matching grant for $125,000 under the State of Michigan’s Emerging Technology Fund (ETF) to help support and expand the efforts under this program.

“We are pleased to have received the Air Force award, which serves as strong validation of our Phase I contract activities, as well as our overall work in the area of nano-particle based biosensors for pathogen and toxin detection,” said Fred Beyerlein, nanoRETE CEO. “We are also very appreciative of the ETF grant, which will enable us to further expand our work and translate it into other potential commercial and employment opportunities. Via both funding and its many support programs, the State of Michigan has proven to be a strong partner in helping nanoRETE to form, develop, and grow.”

October 10, 2012

nanoRETE Appoints Dr. Julia E. Bradsher to its Board of Directors

nanoRETE, Inc. announced today that Julia E. Bradsher, MBA, PhD, has joined its Board of Directors. Dr. Bradsher currently serves as the President and CEO of the Battle Creek, Michigan-based Global Food Protection Institute.

“Dr. Bradsher’s extensive product and marketing skills makes her a perfect fit with our needs going forward,” said Fred Beyerlein, CEO of nanoRETE. “The Global Food Protection Institute, through its technology initiative, is an early investor in nanoRETE and Dr. Bradsher has been very supportive of our efforts to develop a ‘real-time’ detection and screening product. I have worked with Dr. Bradsher in the past and I look forward to expanding that relationship going forward.”

“My appointment to the Board of Directors of nanoRETE is a great honor,” said Dr. Bradsher. “I look forward to working with the other Board members and the leadership team to advance the great work of this innovative company.”

The Global Food Protection Institute is a 501(c)(3) nonprofit organization driving the adoption of food-protection policies and practices for a safer global food supply. The Institute’s mission is to improve public health and reduce mortality, morbidity and economic costs associated with foodborne illnesses through three core initiatives:

  • The Emerging Technology Accelerator is advancing the development of transformative food safety technologies.
  • The International Food Protection Training Institute is building the training infrastructure for the national integrated food safety system.
  • Imagined Food Futures ® is convening foremost thought leaders to identify and address critical food safety issues.